Our first step towards unlocking lung cancer was learning to differentiate the disease subtypes such as small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC); lung cancer responds significantly better to targeted treatments. Our robust menu of tissue diagnostics for early detection, liquid biopsies for sustainable monitoring, in addition to immunohistochemistry (IHC) diagnostic assays and staining products, clinical reagents and fully automated staining platforms ensure highly sensitive and accurate diagnostic results to support all treatment decisions.
New immunotherapy (using the body’s own immune cells to attack cancer cells) has demonstrated great promise for patients with advanced NSCLC. This type of personalised medicine is providing hope for patients already diagnosed with lung cancer with drugs that are effective based on specific characteristics of their tumour. Key biomarkers with known targeted therapies that today can be detected with diagnostics systems include EGFR, ALK, ROS1 and PD-L1.